About
Mendra, founded in 2025 in San Francisco, USA, uses AI to accelerate the in-licensing, development, and commercialization of rare disease therapies.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-01Series A$82M
Investors · 8VC, OrbiMed Advisors, 5AM Ventures, Lux Capital, Wing VCSource · SVTR Weekly #141
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Mendra
AI to accelerate in-licensing, development and commercialization of rare disease therapies
Series A · $82M · 2026-01
$82M
United States
BusinessLatest roundTotal raisedDateChina
BusinessLatest roundTotal raisedDateEurope
BusinessLatest roundTotal raisedDate- Tortus
UCL AI Centre spinout commercializing then-latest graph neural network models as AI assistants that reduce clinicians' medical errors
Undisclosed · $4M · 2024-02
$4M - Amply
AI-accelerated development of gene-silencing therapies for aggressive cancers and inhaled antimicrobials for drug-resistant infections
Seed · $4M · 2025-05
$4M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 26 at a nearby stage · 36 in Silicon Valley
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 33 at a nearby stage · 31 in Silicon Valley
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 12 at a nearby stage · 22 in Silicon Valley
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 10 at a nearby stage · 20 in Silicon Valley
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 6 at a nearby stage · 15 in Silicon Valley
Request intro →Lightspeed
17 Life Sciences deals in the last 24 months · 11 at a nearby stage · 15 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.